Session Information
Date: Monday, June 20, 2016
Session Title: Epidemiology
Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To investigate the impact of diabetes mellitus (DM) and hyperglycemia in early de novo (untreated) Parkinson’s disease (PD) patients.
Background: Patients affected by DM and hyperglycemia are at increased risk of developing PD. The coexistence of DM/hyperglycemia and PD has been associated with postural instability, cognitive impairment and faster disease progression. No studies have evaluated the prevalence and the role of DM and hyperglycemia in early de novo PD patients.
Methods: In this study, data on comorbidities of early de novo PD patients (n=411) were extracted and analyzed using the Parkinson’s Progression Marker’s Initiative database. The presence of DM/ hyperglycemia was defined as history of DM/plasma glucose levels over 126 mg/Dl in two different measures. We investigated motor and non-motor PD features, [123I]FP-CIT SPECT molecular imaging and CSF biomarkers in PD patients with and without DM/hyperglycemia.
Results: 8.3% (34/411) of PD patients had DM/ hyperglycemia. PD patients with DM/ hyperglycemia had lower UPSIT (19.6±7.1 vs 22.6±8.3, p=0.045) and lower MDS-UPDRS Part-II (4.5 vs 6, p=0.047) scores compared to PD patients without DM/ hyperglycemia. There were no differences in motor scores (MDS-UPRDS Part-III, H&Y stage) or nigrostriatal dysfunction ([123I]FP-CIT putamen and caudate uptake values) between PD patients with and without DM/ hyperglycemia. PD patients with DM/ hyperglycemia had higher CSF total Tau (53±26 vs 44.8±19.6, p=0.010) and serum urate (351.5±75.5 vs 314.5±78.5, p=0.010), but no differences in CSF α-synuclein, Aβ1-42, pTau181 and serum IGF1 levels compared to PD patients without DM/ hyperglycemia.
Conclusions: The presence of DM/ hyperglycemia in early de novo PD patients is associated with worse olfaction, worse motor aspects of experiences of daily living, higher CSF Tau pathology and higher serum urate levels. Our findings provide evidence that DM and hyperglycemia exacerbates PD pathology early in the course of the disease.
To cite this abstract in AMA style:
S. Polychronis, G. Pagano, M. Politis. The role of diabetes mellitus and hyperglycemia in early de novo Parkinson’s disease patients [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/the-role-of-diabetes-mellitus-and-hyperglycemia-in-early-de-novo-parkinsons-disease-patients/. Accessed October 23, 2026.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-role-of-diabetes-mellitus-and-hyperglycemia-in-early-de-novo-parkinsons-disease-patients/